Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study

Background. In recent years, evidence supporting multimodality treatment for oesophageal, oesophagogastric junction (OGJ), and gastric cancer has accumulated. This population-based cohort-study investigates trends and predictors of utilisation of multimodality treatment for oesophagogastric cancer in the Netherlands. Patients and methods. Data were obtained from the Netherlands Cancer Registry regarding patients with oesophageal (n = 5450), OGJ (n = 2168) and gastric cancer (n = 6683) without distant metastases who had undergone R0 or R1 surgery diagnosed between 2000 and 2012. Follow-up was completed until February 2014. Preoperative/postoperative chemotherapy and/or radiotherapy combined with surgery were considered multimodality treatment. Logistic regression analysis was performed to analyse the association of age, gender, socioeconomic status, clinical T and N classification, hospital type, comprehensive cancer centre network region, and year of diagnosis, with multimodality treatment receipt. Additional analyses were performed to explore differences in trends of utilisation of multimodality treatment between academic and non-academic hospitals. Results. Multimodality treatment utilisation for oesophageal, OGJ and gastric cancer increased significantly to 90%, 85% and 56% in 2012, respectively. In oesophageal and OGJ cancer patients, preoperative chemoradiotherapy was most frequently administered (85% and 47% in 2012, respectively), and in gastric cancer patients preoperative chemotherapy (47% in 2012). Lower age, higher clinical T and N classification, and diagnosis in more recent years were significantly associated with more frequent multimodality treatment receipt. The adoption of most types of multimodality treatment in academic hospitals preceded non-academic hospitals by a year. Conclusion. In the Netherlands, the utilisation of multimodality treatment for oesophagogastric cancer has significantly increased during the past decade, especially in oesophageal and OGJ cancer. Multimodality treatment utilisation was especially dependent on patient and tumour characteristics and year of diagnosis, but multimodality treatment trends seem to be related to the publication of landmark studies, participation in nationally running clinical trials, and hospital type, preceding national guidelines.

[1]  P. Pfeiffer,et al.  Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer , 2014, Acta oncologica.

[2]  A. Benson,et al.  Treatment Trends and Predictors of Adjuvant and Neoadjuvant Therapy for Gastric Adenocarcinoma in the United States , 2013, Annals of Surgical Oncology.

[3]  J. Ajani,et al.  Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[5]  H. Putter,et al.  Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. , 2012, European journal of cancer.

[6]  H. Putter,et al.  Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) , 2011, BMC Cancer.

[7]  L. Rabeneck,et al.  Management of gastric cancer in Ontario , 2010, Journal of surgical oncology.

[8]  H. Putter,et al.  Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Putter,et al.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.

[10]  L. Clegg,et al.  Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. , 2008, World journal of gastroenterology.

[11]  A. Kiss,et al.  Adjuvant therapy for resected gastric cancer--rapid, yet incomplete adoption following results of intergroup 0116 trial. , 2008, International journal of radiation oncology, biology, physics.

[12]  J. Lagergren,et al.  Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population-based Study , 2006, World Journal of Surgery.

[13]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[14]  Robert E Harbaugh,et al.  Surgeon Volume and Operative Mortality in the United States. , 2004, Neurosurgery.

[15]  J. Birkmeyer,et al.  Hospital volume and surgical mortality in the United States. , 2002, The New England journal of medicine.

[16]  M. Iannettoni,et al.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[18]  J. Jager,et al.  Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. , 1993, British Journal of Cancer.

[19]  M. Verheij,et al.  Oesophagogastric cancer: exploring the way to an individual approach , 2015 .

[20]  M. Coleman,et al.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. , 2014, The Lancet. Oncology.

[21]  Stephen B. Edge,et al.  Comprar AJCC Cancer Staging Manual + cd-rom 7th Ed | Trotti, Andrea | 9780387884400 | Springer , 2009 .

[22]  ten,et al.  UvA-DARE (Digital Academic Repository) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma the esophagus , 2002 .

[23]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[24]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .